AI Companies Face Proposed Ban on Selling Health Data

A bipartisan push in Congress is seeking to dramatically tighten restrictions on how artificial intelligence firms can use personal health data. Recent legislative proposals aim to prevent AI companies from selling or transferring American consumers’ health and location information—whether collected directly or entered into AI chatbots during everyday use. This legislative effort reflects growing public and regulatory concern about privacy as conversational AI tools become increasingly integrated into healthcare and personal wellness spaces.

Modern AI chatbots and health applications collect and process highly sensitive data from millions of users. Many users, often unknowingly, provide intimate health details or share their location with AI-powered applications like ChatGPT, Claude, and various symptom-checker bots. With insufficient federal safeguards, some AI companies have relied on third-party data brokers, raising concerns about how this data may be used or monetized. The potential for health and location information to be sold or misused is at the heart of the renewed legislative scrutiny.

The proposed legislation, championed by Senator Elizabeth Warren of Massachusetts and Representative Mary Gay Scanlon of Pennsylvania, is part of a larger trend to overhaul how health and location data is handled in the U.S. Building on previous efforts to restrict data brokers, this new bill directly targets AI-driven entities, aiming to make it illegal for them to profit from highly personal information. Such moves would close significant regulatory loopholes that have allowed data collected by non-traditional healthcare platforms to be traded and sold.

For businesses operating in the AI and health technology sectors, these regulatory changes could have far-reaching effects. Firms handling health and location data will need to overhaul compliance practices, invest in stronger data governance, and rethink monetization strategies that rely on data sales. More broadly, the move promises to boost consumer trust in digital health solutions—so long as organizations prioritize privacy and transparency. Businesses failing to adapt risk penalties and reputational damage in an increasingly privacy-conscious marketplace.

Stricter rules on health data sales are not just about consumer privacy—they also shape the future of AI innovation. Responsible data stewardship can help companies differentiate themselves and demonstrate value to users, clients, and partners. As lawmakers and regulators raise the bar for health data handling, proactive organizations can position themselves as leaders in ethical AI and privacy-first business models. The coming months will be critical for the AI sector, as new rules solidify expectations on data usage and reshape industry standards.